Table 1.
Characteristics of patients who responded to the Internet survey and self-reported a physician diagnosis of gout (N = 499)
| Characteristics | N or n/N | %a or mean ± SD |
|---|---|---|
| Age, mean ± SD (range) | 497 | 56.3 ± 12.6 (25–93) |
| Age groups, % | ||
| 21–40 | 61 | 12.2 |
| 41–60 | 244 | 48.9 |
| 61–80 | 179 | 35.9 |
| ≥80 | 13 | 2.6 |
| Missing | 2 | 0.4 |
| Sex, % | ||
| Male | 368 | 73.7 |
| Female | 131 | 26.3 |
| Race, % | ||
| White/Caucasian | 371 | 74.3 |
| African American | 38 | 7.6 |
| Hispanic or Latino | 14 | 2.8 |
| Asian | 45 | 9.0 |
| American Indian or Alaskan Native | 3 | 0.6 |
| Hawaiian or Pacific Islander | 9 | 1.8 |
| Other | 18 | 3.6 |
| Missing | 1 | 0.2 |
| Patients prescribed Allopurinol/Febuxostat, % | 285 | 57.1 |
| Number of days gout medication missed in past 30 days, mean ± S.D. | 251 | 4.50 ± 8.72 |
| Of those prescribed ULT, n/N (%) | ||
| On ULT | 250/285 | 88 |
| Quit ULT | 20/285 | 7 |
| Taking ULT infrequently | 2/285 | 0.7 |
| Missing/did not respond | 13/285 | 4.5 |
| Days ULT missed in past 30 days, n/N (%) | ||
| 0 days (adherence 100 %) | 148/251 | 59 |
| 1–5 days (adherence >80 %) | 49/251 | 19.5 |
| 6–14 days (adherence, 51–80 %) | 26/251 | 10.3 |
| >15 days (adherence, ≤50 %) | 28/251 | 11.2 |
| Best life-long treatment choice, % | ||
| Cherry extract | 122 | 24.4 |
| Diet modification | 79 | 15.8 |
| ULT | 277 | 55.5 |
| None | 21 | 4.2 |
| Likelihood of making life-long change to diet (0–10), % | ||
| 0–8 | 308 | 61.7 |
| 9–10 | 191 | 38.3 |
aAll numbers are percent except for age and the number of days gout medication was missed
ULT Urate lowering therapy, SD standard deviation